Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression?

Amir Toussi, Suzanne Merrill, Stephen A. Boorjian, Sarah P. Psutka, R. Houston Thompson, Igor Frank, Matthew K. Tollefson, Matthew T. Gettman, Rachel E. Carlson, Laureano J. Rangel, R. Jeffrey Karnes

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Purpose Multiple definitions of biochemical recurrence for prostate cancer exist after radical prostatectomy, and variation continues in prostate cancer outcome reporting and secondary treatment initiation. We reviewed long-Term prostatectomy outcomes to assess the most appropriate prostate specific antigen cut point that predicts future disease progression. Materials and Methods We identified 13,512 patients with cT1-2N0M0 prostate cancer who underwent radical prostatectomy between 1987 and 2010. Single prostate specific antigen cut points of 0.2, 0.3, 0.4 and 0.5 ng/ml or greater, as well as confirmatory prostate specific antigen value definitions of 0.2 ng/ml or greater followed by prostate specific antigen greater than 0.2 ng/ml and 0.4 ng/ml or greater followed by prostate specific antigen greater than 0.4 ng/ml were tested. Continued prostate specific antigen increase after a designated cut point definition was estimated using cumulative incidence. The strength of association between biochemical recurrence definitions and subsequent systemic progression were analyzed using Cox proportional hazard models and the O'Quigley event based R2 test. Results At a median postoperative followup of 9.1 years (IQR 4.9-14.3) a detectable prostate specific antigen developed in 5,041 patients and systemic progression developed in 512. After reaching the prostate specific antigen cut point of 0.2, 0.3 and 0.4 ng/ml, the percentage of patients experiencing a continued prostate specific antigen increase over 5 years was 61%, 67% and 74%, respectively, plateauing at 0.4 ng/ml. The strongest association between biochemical recurrence and systemic progression occurred using a single prostate specific antigen cut point of 0.4 ng/ml or greater (HR 36, R2 0.92). Conclusions A prostate specific antigen cut point of 0.4 ng/ml or greater reflects the threshold at which a prostate specific antigen increase becomes durable and shows the strongest correlation with subsequent systemic progression. Consideration should be given to using a prostate specific antigen of 0.4 ng/ml or greater as the standard biochemical recurrence definition after radical prostatectomy.

Original languageEnglish (US)
Pages (from-to)1754-1759
Number of pages6
JournalJournal of Urology
Volume195
Issue number6
DOIs
StatePublished - Jun 1 2016

Fingerprint

Prostate-Specific Antigen
Prostatectomy
Recurrence
Prostatic Neoplasms
Proportional Hazards Models
Disease Progression

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Toussi, Amir ; Merrill, Suzanne ; Boorjian, Stephen A. ; Psutka, Sarah P. ; Houston Thompson, R. ; Frank, Igor ; Tollefson, Matthew K. ; Gettman, Matthew T. ; Carlson, Rachel E. ; Rangel, Laureano J. ; Jeffrey Karnes, R. / Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression?. In: Journal of Urology. 2016 ; Vol. 195, No. 6. pp. 1754-1759.
@article{87c7b36e67124557837b5ca890e58a44,
title = "Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression?",
abstract = "Purpose Multiple definitions of biochemical recurrence for prostate cancer exist after radical prostatectomy, and variation continues in prostate cancer outcome reporting and secondary treatment initiation. We reviewed long-Term prostatectomy outcomes to assess the most appropriate prostate specific antigen cut point that predicts future disease progression. Materials and Methods We identified 13,512 patients with cT1-2N0M0 prostate cancer who underwent radical prostatectomy between 1987 and 2010. Single prostate specific antigen cut points of 0.2, 0.3, 0.4 and 0.5 ng/ml or greater, as well as confirmatory prostate specific antigen value definitions of 0.2 ng/ml or greater followed by prostate specific antigen greater than 0.2 ng/ml and 0.4 ng/ml or greater followed by prostate specific antigen greater than 0.4 ng/ml were tested. Continued prostate specific antigen increase after a designated cut point definition was estimated using cumulative incidence. The strength of association between biochemical recurrence definitions and subsequent systemic progression were analyzed using Cox proportional hazard models and the O'Quigley event based R2 test. Results At a median postoperative followup of 9.1 years (IQR 4.9-14.3) a detectable prostate specific antigen developed in 5,041 patients and systemic progression developed in 512. After reaching the prostate specific antigen cut point of 0.2, 0.3 and 0.4 ng/ml, the percentage of patients experiencing a continued prostate specific antigen increase over 5 years was 61{\%}, 67{\%} and 74{\%}, respectively, plateauing at 0.4 ng/ml. The strongest association between biochemical recurrence and systemic progression occurred using a single prostate specific antigen cut point of 0.4 ng/ml or greater (HR 36, R2 0.92). Conclusions A prostate specific antigen cut point of 0.4 ng/ml or greater reflects the threshold at which a prostate specific antigen increase becomes durable and shows the strongest correlation with subsequent systemic progression. Consideration should be given to using a prostate specific antigen of 0.4 ng/ml or greater as the standard biochemical recurrence definition after radical prostatectomy.",
author = "Amir Toussi and Suzanne Merrill and Boorjian, {Stephen A.} and Psutka, {Sarah P.} and {Houston Thompson}, R. and Igor Frank and Tollefson, {Matthew K.} and Gettman, {Matthew T.} and Carlson, {Rachel E.} and Rangel, {Laureano J.} and {Jeffrey Karnes}, R.",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.juro.2015.12.075",
language = "English (US)",
volume = "195",
pages = "1754--1759",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

Toussi, A, Merrill, S, Boorjian, SA, Psutka, SP, Houston Thompson, R, Frank, I, Tollefson, MK, Gettman, MT, Carlson, RE, Rangel, LJ & Jeffrey Karnes, R 2016, 'Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression?', Journal of Urology, vol. 195, no. 6, pp. 1754-1759. https://doi.org/10.1016/j.juro.2015.12.075

Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression? / Toussi, Amir; Merrill, Suzanne; Boorjian, Stephen A.; Psutka, Sarah P.; Houston Thompson, R.; Frank, Igor; Tollefson, Matthew K.; Gettman, Matthew T.; Carlson, Rachel E.; Rangel, Laureano J.; Jeffrey Karnes, R.

In: Journal of Urology, Vol. 195, No. 6, 01.06.2016, p. 1754-1759.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression?

AU - Toussi, Amir

AU - Merrill, Suzanne

AU - Boorjian, Stephen A.

AU - Psutka, Sarah P.

AU - Houston Thompson, R.

AU - Frank, Igor

AU - Tollefson, Matthew K.

AU - Gettman, Matthew T.

AU - Carlson, Rachel E.

AU - Rangel, Laureano J.

AU - Jeffrey Karnes, R.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Purpose Multiple definitions of biochemical recurrence for prostate cancer exist after radical prostatectomy, and variation continues in prostate cancer outcome reporting and secondary treatment initiation. We reviewed long-Term prostatectomy outcomes to assess the most appropriate prostate specific antigen cut point that predicts future disease progression. Materials and Methods We identified 13,512 patients with cT1-2N0M0 prostate cancer who underwent radical prostatectomy between 1987 and 2010. Single prostate specific antigen cut points of 0.2, 0.3, 0.4 and 0.5 ng/ml or greater, as well as confirmatory prostate specific antigen value definitions of 0.2 ng/ml or greater followed by prostate specific antigen greater than 0.2 ng/ml and 0.4 ng/ml or greater followed by prostate specific antigen greater than 0.4 ng/ml were tested. Continued prostate specific antigen increase after a designated cut point definition was estimated using cumulative incidence. The strength of association between biochemical recurrence definitions and subsequent systemic progression were analyzed using Cox proportional hazard models and the O'Quigley event based R2 test. Results At a median postoperative followup of 9.1 years (IQR 4.9-14.3) a detectable prostate specific antigen developed in 5,041 patients and systemic progression developed in 512. After reaching the prostate specific antigen cut point of 0.2, 0.3 and 0.4 ng/ml, the percentage of patients experiencing a continued prostate specific antigen increase over 5 years was 61%, 67% and 74%, respectively, plateauing at 0.4 ng/ml. The strongest association between biochemical recurrence and systemic progression occurred using a single prostate specific antigen cut point of 0.4 ng/ml or greater (HR 36, R2 0.92). Conclusions A prostate specific antigen cut point of 0.4 ng/ml or greater reflects the threshold at which a prostate specific antigen increase becomes durable and shows the strongest correlation with subsequent systemic progression. Consideration should be given to using a prostate specific antigen of 0.4 ng/ml or greater as the standard biochemical recurrence definition after radical prostatectomy.

AB - Purpose Multiple definitions of biochemical recurrence for prostate cancer exist after radical prostatectomy, and variation continues in prostate cancer outcome reporting and secondary treatment initiation. We reviewed long-Term prostatectomy outcomes to assess the most appropriate prostate specific antigen cut point that predicts future disease progression. Materials and Methods We identified 13,512 patients with cT1-2N0M0 prostate cancer who underwent radical prostatectomy between 1987 and 2010. Single prostate specific antigen cut points of 0.2, 0.3, 0.4 and 0.5 ng/ml or greater, as well as confirmatory prostate specific antigen value definitions of 0.2 ng/ml or greater followed by prostate specific antigen greater than 0.2 ng/ml and 0.4 ng/ml or greater followed by prostate specific antigen greater than 0.4 ng/ml were tested. Continued prostate specific antigen increase after a designated cut point definition was estimated using cumulative incidence. The strength of association between biochemical recurrence definitions and subsequent systemic progression were analyzed using Cox proportional hazard models and the O'Quigley event based R2 test. Results At a median postoperative followup of 9.1 years (IQR 4.9-14.3) a detectable prostate specific antigen developed in 5,041 patients and systemic progression developed in 512. After reaching the prostate specific antigen cut point of 0.2, 0.3 and 0.4 ng/ml, the percentage of patients experiencing a continued prostate specific antigen increase over 5 years was 61%, 67% and 74%, respectively, plateauing at 0.4 ng/ml. The strongest association between biochemical recurrence and systemic progression occurred using a single prostate specific antigen cut point of 0.4 ng/ml or greater (HR 36, R2 0.92). Conclusions A prostate specific antigen cut point of 0.4 ng/ml or greater reflects the threshold at which a prostate specific antigen increase becomes durable and shows the strongest correlation with subsequent systemic progression. Consideration should be given to using a prostate specific antigen of 0.4 ng/ml or greater as the standard biochemical recurrence definition after radical prostatectomy.

UR - http://www.scopus.com/inward/record.url?scp=84963591557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963591557&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2015.12.075

DO - 10.1016/j.juro.2015.12.075

M3 - Article

C2 - 26721226

AN - SCOPUS:84963591557

VL - 195

SP - 1754

EP - 1759

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -